| Bioactivity | HHQ16 is an orally active derivative of Astragaloside IV (HY-N0431). HHQ16 effectively reverses infarction-induced hypertrophy and heart failure by targeted degrading lnc4012/lnc9456 and antagonizing their effects on G3BP2/NF-κB signaling[1]. |
| Invitro | HHQ16 (100 nM，6 小时) 与 lnc9456 高亲和力结合，并诱导其在 HL-1 小鼠心肌细胞中降解[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> HHQ16 相关抗体: |
| In Vivo | HHQ16 (1-100 mg/kg，口服灌胃，每日一次，持续 4 周) 可有效逆转左冠状动脉前降支结扎 (LADL) 引起的小鼠心功能恶化和结构重塑[1]。HHQ16 (10 mg/kg，口服，2 周) 可降低 AAV-lnc9456 小鼠心脏中高水平的 lnc9456，并消除与重塑相关的变化[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 2620471-66-9 |
| Formula | C30H48F2O4 |
| Molar Mass | 510.70 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wan J, et al. Astragaloside IV derivative HHQ16 ameliorates infarction-induced hypertrophy and heart failure through degradation of lncRNA4012/9456. Signal Transduct Target Ther. 2023 Oct 19;8(1):414. |